Contemporary management of patients with stable ischemic heart disease


In the current issue of Cardiovascular Innovations and Applications (Special Issue on Stable Ischemic Heart Disease, Volume 3, Number 3, 2019, pp. 269-278(10); DOI, Radmila Lyubarova, Joshua Schulman-Marcus and William E. Boden from the Division of Cardiology, Department of Medicine, Albany Medical Center, Albany, NY, USA and VA New England Healthcare System, Boston, MA, USA consider contemporary management of patients with stable ischemic heart disease.

Angina persists for many patients despite medical therapy and/or revascularization. In all patients with angina, aggressive risk factor modification and optimized medical management must be instituted. Revascularization should be performed for high-risk patients or patients with persistent symptoms. A beta-blocker is likely a first-line agent; how-ever, most patients require multiple medications for symptom control. Novel agents with new mechanisms improve treatment options, including ivabradine (sinus node inhibitor), and late Na+blockade (with a mechanism of action complementary to traditional agents) is beneficial in a broad range of patients unresponsive to current treatment options. Ongoing trials may help better define the role of aggressive medical therapy with or without revascularization.


CVIA is available on the IngentaConnect platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. CVIA is indexed in the EMBASE, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Media Contact
Morgan Lyons
[email protected]

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More